Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Eftilagimod alpha |
Trade Name | |
Synonyms | IMP321|LAG-31g|Immufact |
Drug Descriptions |
Eftilagimod alpha (IMP321) is a recombinant soluble LAG3 protein, which binds to MHC Class II molecules, resulting in increased dendritic cell maturation and potentially leading to enhanced anti-tumor immune response (PMID: 16621192, PMID: 17785860, PMID: 20653948, PMID: 30977393). |
DrugClasses | |
CAS Registry Number | 1800476-36-1 |
NCIT ID | C62509 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + Eftilagimod alpha | Avelumab Eftilagimod alpha | 0 | 1 |
Eftilagimod alpha | Eftilagimod alpha | 0 | 1 |
Eftilagimod alpha + Paclitaxel | Eftilagimod alpha Paclitaxel | 0 | 1 |
Eftilagimod alpha + Pembrolizumab | Eftilagimod alpha Pembrolizumab | 0 | 2 |